Satish Jindal

Satish Jindal is a General Partner at Advent Life Sciences and concurrently serves as the Chief Executive Officer and Director of Aleta Biotherapeutics. Previously, he operated as the Chief Executive Officer of BioMotiv and held Vice President and Site Head positions at major pharmaceutical firms, including Schering-Plough and Bristol-Myers Squibb. As a serial biotech entrepreneur, Jindal co-founded NeoGenesis, which was subsequently acquired by Schering-Plough, and served as co-founder and President of the publicly traded oncology company Verastem. He also co-founded Elicio Therapeutics and currently maintains a board position at Epitopea, an RNA cancer immunotherapy developer that recently secured $31 million in pre-Series A financing. Following his postdoctoral research at the Whitehead Institute at MIT, Jindal maintains a professional focus on advancing early-stage life sciences, immuno-oncology, and cell therapy investments across the biotechnology sector.